07:33 EDT Soleno jumps 11% to $63.37 after Acadia trial miss
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Positive Market Outlook for Soleno Therapeutics’ Vykat XR in Prader-Willi Syndrome Treatment
- Wells Fargo would be buyers of Soleno amid FAERS update weakness
- Soleno Therapeutics Addresses FDA Adverse Event Report
- Soleno concludes serious adverse reported in FAERS not related to VYKAT XR
- LifeScience Cap’s Optimistic Outlook on Soleno Therapeutics: Vykat XR’s Promising Market Potential and Expansion Plans